Ceri Bygrave

Aug 24, 2024 | oncodaily.com | Ceri Bygrave

Martin Kaiser, Reader in Molecular Haematology at The Institute of Cancer Research, shared a post on LinkedIn:“Happy to highlight the British Society of Haematology BSH / UK Myeloma Society UKMS Good Practice Paper on Diagnosis and initial treatment of high-risk myeloma. It is written with access challenges for patients to diagnostics and treatments in mind and can hopefully support access discussions in this context.

Jan 3, 2024 | onlinelibrary.wiley.com | Ceri Bygrave |Jahanzaib Khwaja |Joshua Bomsztyk |Maria Atta

CONFLICT OF INTEREST STATEMENT JK, JB, MA, CB, AF, SD, SF, JT, PP, GB, CC, OS, RB, RS, AR and SM: nil to declare. MG: honoraria—Janssen, Amgen and Alnylam; travel support—Novartis, Janssen, Takeda, Stemline therapeutics; consultant—Amgen, Sanofi, Celgene, Stemline therapeutics, Janssen; honoraria—Janssen, Amgen, Alnylam. KJ: Advisory Boards—GSK. AW: honoraria—GSK, Alexion, Attralus, Janssen; travel support—Takeda. REFERENCES 1, , , , , , et al.

Jun 16, 2023 | rcpath.org | Ceri Bygrave

A day of lectures and discussions from a leading expert faculty exploring “What’s New in Haematological Malignancies” for healthcare professionals from the region. TOPIC COVERED An expert faculty to be on-site for lectures and discussions to explore “What’s New in Haematological Malignancies’. WHO SHOULD ATTEND?